drugset / Trial / NCT04206254
GP96 Heat Shock Protein-Peptide Complex Vaccine in Treating Patients With Liver Cancer
Phase 2/3
Unknown
80 enrolled
Cure&Sure Biotech Co., LTD
Cancer Institute and Hospital, Chinese Academy of Medical Sciences · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This trial is to further study the safety and effectiveness of autologous gp96 treatment of liver cancer on the basis of preliminary work
Timeline
- Start
- 2019-12-19
- Primary completion
- 2022-08-05
- Completion
- 2023-08-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | vitespen | Vaccine | 25 ug | Subcutaneous |